News

 

NST doses first patient in Phase 2b clinical study of icosabutate in NASH (‘ICONA’)

Naarden, The Netherlands, 25 September 2019 – NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative strategies for the treatment of NASH (Non-alcoholic Steatohepatitis) and other metabolic, inflammatory and fibrotic diseases, today announces dosing of the first patient with icosabutate in a phase 2b dose ranging study (‘ICONA’).

Icosabutate latest data shows direct and potent anti-fibrotic effect in both differentiated rodent NASH models and human stellate cells

Naarden, The Netherlands, 9 November 2018 – NorthSea Therapeutics B.V., (‘NST’) a newly established Dutch biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic, inflammatory and fibrotic diseases, today announces the publication of two posters to be presented at the AASLD The Liver MeetingTM 2018 in San Francisco on 9-13 November. The posters will outline the Company’s latest research data of its lead product’s anti-fibrotic effect in both differentiated rodent NASH models and human stellate cells.

Potential of icosabutate as a novel approach to the treatment of NASH highlighted in late-breaker at The International Liver CongressTM 2018

Naarden, The Netherlands, 12 April 2018 – NorthSea Therapeutics B.V., (‘NST’) a newly established Dutch biotech company aiming to develop novel and innovative strategies for the treatment of NASH and other metabolic, inflammatory and fibrotic diseases, announces the publication of a late-breaker abstract and poster to be presented at The EASL International Liver CongressTM 2018 in Paris on 12-14 April.

“We believe icosabutate has the potential to impact the lives of millions of NASH patients globally”
Rob de Ree

Chief Executive Officer, NorthSea Therapeutics

Voor meer informatie:

info@northseatherapeutics.com

+31 (0) 35 760 65 05